Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?

Medical Hypotheses

Volumn 70, Issue 3, 2008, Pages 512-514

  Zhao, Fu Hai ^a   Chen, Yun Dai ^a   Jin, Ze Ning ^a   Lu, Shu Zheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; METAL; PACLITAXEL; POLYMER; PROTEIN KINASE B; RAPAMYCIN;

ARTERY INJURY; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL THERAPY; CELL TRANSPLANTATION; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HYPERPLASIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STEM CELL; THROMBOCYTE AGGREGATION; THROMBOSIS;

CELL DIVISION; CELL MOVEMENT; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; ERYTHROID PROGENITOR CELLS; HUMANS; PACLITAXEL; SIROLIMUS; STENTS; THROMBOSIS; TREATMENT FAILURE;

MELO;

EID: 38849115805     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.05.055     Document Type: Article

References (24)

1. Tsimikas S. Drug-eluting stents and late adverse clinical outcomes. J Am Coll Cardiol 47 (2006) 2112-2115
2. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions. Circulation 108 (2003) 788-794
3. Kedia G., and Lee M.S. Stent thrombosis with drug-eluting stents: a re-examination of the evidence. Catheter Cardiovasc Interv 69 (2007) 782-789
4. Urao N., Okigaki M., Yamada H., et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 98 (2006) 1405-1413
5. Griese D.P., Ehsan A., Melo L.G., et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 108 (2003) 2710-2715
6. Butzal M., Loges S., Schweizer M., et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 300 (2004) 65-71
7. Chen T.G., Chen J.Z., and Wang X.X. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Proliferat 39 (2006) 117-125
8. Marx S.O., Jayaraman T., Go L.O., et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
9. Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277-2283
10. Steffel J., Luscher T.F., and Tanner F.C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113 (2006) 722-731
11. Steffel J., Latini R.A., Akhmedov A., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 (2005) 2002-2011
12. Guha M., and Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277 (2002) 32124-32132
13. 2 kinase activation. Circ Res 99 (2006) 149-155
14. Lüscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
15. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
16. Farb A., Burke A.P., Kolodgie F.D., et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
17. Guagliumi G., Farb A., Musumeci G., et al. Images in cardiovascular medicine: sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 107 (2003) 1340-1341
18. Asahara T., Murohara T., Sullivan M., et al. Isolation of putative progenitor cells for angiogenesis. Science 275 (1997) 964-967
19. Shi Q., Rafii S., Wu M.H., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92 (1998) 362-367
20. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97 (2000) 3422-3427
21. Fukuda D., Sata M., Tanaka K., et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111 (2005) 926-931
22. Imanishi T., Kobayashi K., Kuki S., et al. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 189 (2006) 288-296
23. Halkin A., and Stone G.W. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 17 (2004) 271-282
24. Kereiakes D.J., Choo J.K., Young J.J., et al. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 5 (2004) 9-15